| Document |
Document Title |
|
WO/2021/094902A1 |
The present specification relates to once daily dual release compositions of nicorandil. The specification also relates to pharmaceutical unit composition comprising metoprolol and nicorandil or pharmaceutically acceptable salt thereof w...
|
|
WO/2021/088885A1 |
The present invention relates to the technical field of chemical medicine, in particular to a compound targeting type I PRMT, a preparation method therefor, and an application thereof. The compound A and a pharmaceutically acceptable sal...
|
|
WO/2021/092246A1 |
Described herein are TYK2 pseudokinase ligands and methods of utilizing TYK2 pseudokinase ligands in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2021/088859A1 |
An indazole derivative having the structure as represented by formula (I), or a pharmaceutically acceptable salt of same, or a stereoscopic isomer of same, and, a pharmaceutical composition of same, and applications thereof. The compound...
|
|
WO/2021/085263A1 |
3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethyl-2,3-dihydro-1
H-inden-4-yl)-1H-pyrazole-4-carboxamide in at least one crystal form selected from the group consisting of Ra1 form, Ra2 form, and Ra3 form, which respectively show the sets of...
|
|
WO/2021/083060A1 |
The present invention relates to a five-membered heterocyclic oxocarboxylic acid compound and the medical use thereof. Specifically, the present invention relates to a compound as represented by formula (I) and a pharmaceutically accepta...
|
|
WO/2021/086882A1 |
The present disclosure encompasses solid state forms of Arry-797, in embodiments crystalline polymorphs or salts or co-crystals of Arry-797, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2021/082997A1 |
An amide compound containing a substituted acetophenone structure fragment, having a structure shown as general formula I. Please see the description for the definitions of substituents in the formula. The compound has a broad-spectrum b...
|
|
WO/2021/085370A1 |
The present invention addresses the problem of providing an excellent pesticide. The prevent invention provides an azole derivative or an agrochemically acceptable salt thereof and a pesticide characterized by comprising the same as an...
|
|
WO/2021/079069A1 |
The present invention relates to novel energetic salts of formula C+A-, wherein: C+ is a cation derived from an amino acid; A- is an energetic nitrogen-containing anion chosen among the anions derived from dinitramide, trinitromethane (N...
|
|
WO/2021/078076A1 |
A novel crystalline form of acetylated eltrombopag and a preparation method thereof belonging to the field of medicinal chemistry. The crystalline form has good stability and facilitates operations in storage, transfer, and production pr...
|
|
WO/2021/080015A1 |
Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds and metho...
|
|
WO/2021/078979A1 |
The present invention relates to a process for the preparation of (Z,2E)-5-[1-(4- chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pe
nt-3-enamide derivatives suitable for use, e.g., as active ingredients, which have microbiocid...
|
|
WO/2021/080929A1 |
The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitor...
|
|
WO/2021/081375A1 |
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
|
|
WO/2021/078077A1 |
Disclosed are a new crystal form of acetylated eltrombopag and a preparation method therefor, belonging to the field of pharmaceutical chemistry. The crystal form has better stability, which is conducive to storage, transfer, and operati...
|
|
WO/2021/076832A1 |
Described herein are novel methods of synthesizing 5-Bromo-2-(3-chloro-pyridin-2-yl)- 2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives. Also described herein are novel reaction intermediates.
|
|
WO/2021/075476A1 |
Provided is a compound which has an effect of inhibiting neuron degeneration, in particular, an effect of inhibiting motor neuron degeneration and which is useful as a prophylactic or therapeutic agent for motor neuron diseases (for exam...
|
|
WO/2021/076831A1 |
Described herein are novel methods of synthesizing 5-Bromo-2-(3-chloro-pyridin-2-yl)- 2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives. Also described herein are novel reaction intermediates.
|
|
WO/2021/076835A1 |
Described herein are novel methods of synthesizing 5-Bromo-2-(3-chloro-pyridin-2-yl)- 2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives. Also described herein are novel reaction intermediates.
|
|
WO/2021/076839A1 |
Described herein are novel methods of synthesizing 5-Bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives. Also described herein are novel reaction intermediates.
|
|
WO/2021/073643A1 |
The present application relates to the field of medicine, relates to drugs for treating non-alcoholic steatohepatitis, in particular, to linked cyclic compounds for treating non-alcoholic steatohepatitis, more in particular, to a compoun...
|
|
WO/2021/076838A1 |
Described herein are novel methods of synthesizing 5-Bromo-2-(3-chloro-pyridin-2-yl)- 2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives.
|
|
WO/2021/073592A1 |
Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors. Specifically, disclosed are hydrochloride and acetate of compounds of formula (I) and crystal forms thereof, as well as application ...
|
|
WO/2021/070150A1 |
The present invention relates to an inhalable composition comprising a therapeutically effective dosage amount of compound (I), 2-{4-[(2S)-1,1-difluoro-2-hydroxypropyl]phenyl}-N-{4-[3-(2-e
thylphenyl) pyrazine-2-yl]phenyl}acetamide or a ...
|
|
WO/2021/068943A1 |
Disclosed in the present invention are a substituted nitrogen heterocyclic compound and anesthetic action thereof. Specifically provided are a chemical compound as shown in formula I, a stereoisomer thereof, a pharmaceutically acceptable...
|
|
WO/2021/068820A1 |
Disclosed in the present invention are an alkene-containing carboxylate compound and use of an agriculturally acceptable salt thereof as a herbicide. Said compound is as represented by general formula (I). The definition of the substitue...
|
|
WO/2021/068815A1 |
Disclosed in the present invention are a carboxylic acid ester compound and an application thereof, the structure of the compound being shown in general formula I, and the definition of each substituent in general formula I being provide...
|
|
WO/2021/071919A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided ...
|
|
WO/2021/070132A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3,...
|
|
WO/2021/067460A1 |
The disclosure provides cryptophycin intermediates, cryptophycin analogs, and cryptophycin chimeric molecules useful in treating cancer, as well as methods of producing these compounds and methods of treating cancer.
|
|
WO/2021/067374A1 |
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of F GFR3-associated diseases such as cancer.
|
|
WO/2021/058754A1 |
The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropi...
|
|
WO/2021/060888A2 |
The present invention relates to a composition for preventing or treating cancer, containing a novel trifluoromethyl phenyl pyrazole derivative as an active ingredient, and, more specifically, to a composition for preventing, alleviating...
|
|
WO/2021/055849A1 |
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...
|
|
WO/2021/047581A1 |
Disclosed is a hexahydrobenzopyrazole compound shown in formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a solvate, a hydrate, an N-oxide, a prodrug, and a pharmaceutical composition thereof, a preparation method ther...
|
|
WO/2021/047407A1 |
A biaryl compound, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The compound has the structure shown in formula I, has a significant regulatory effect on RORγ, can be used as a highly effective...
|
|
WO/2021/047583A1 |
Disclosed is a tricyclic pyrazole compound shown in formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a solvate, a hydrate, an N-oxide, a prodrug, and a pharmaceutical composition thereof, a preparation method therefor...
|
|
WO/2021/047677A1 |
Provided are an IRAK4 kinase inhibitor, and preparation thereof and use thereof, specifically provided are a compound represented by formula (I), a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a pharmaceutically ...
|
|
WO/2021/038419A1 |
Compounds that function as kinase inhibitors are provided. The kinase inhibitors can have any structure of the formulae provided herein, such as shown for Compounds 1-4. A pharmaceutical composition can include: the compound of one of th...
|
|
WO/2021/038490A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3 ...
|
|
WO/2021/036845A1 |
Provided is a substituted benzoyl compound and an application thereof; specifically, provided is a compound represented by formula (I), a preparation method therefor and a use thereof as an herbicide. Q is optionally substituted oxocyclo...
|
|
WO/2021/035788A1 |
A PDGFR kinase inhibitor represented by structural formula (I) as well as use thereof and a method using same for preventing or treating PDGFR kinase activity related diseases.
|
|
WO/2021/037219A1 |
The present invention provides an amide pyrazole compound used as an FGFR irreversible inhibitor, a preparation method therefor, and use thereof. Specifically, the present invention provides a compound of formula I, or a pharmaceutically...
|
|
WO/2021/039824A1 |
An RNA methyltransferase inhibitor containing at least one type of compound selected from the group consisting of sulfonamide-based compounds represented by general formula (1) and pyrazoline-based compounds represented by general formul...
|
|
WO/2021/031984A1 |
Disclosed are a carboxylic acid oxime ester compound and the use thereof as a herbicide and for preparing a microbicide. The carboxylic acid oxime ester compound is as represented by general formula I:
|
|
WO/2021/033165A1 |
The present disclosure relates to a process for the synthesis of pyrazolidinone, particularly alkyl 2-(3-chloropyridin-2-yl)-5-oxo-pyrazolidine-3-carboxylate (pyrazolidinone) compound. The process of the present disclosure is simple, eco...
|
|
WO/2021/033166A1 |
The present disclosure relates to a process for the synthesis of pyrazolidinone, particularly alkyl 2-(3-chloropyridin-2-yl)-5-oxo-pyrazolidine-3-carboxylate (pyrazolidinone) compound. The process of the present disclosure is simple, eco...
|
|
WO/2021/030554A1 |
The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
|
|
WO/2021/028512A1 |
The present invention provides new arylsulfonamide compounds having the general formula (I), wherein L, R1, R2, R3 and R4are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods ...
|
